JP2014520787A5 - - Google Patents

Download PDF

Info

Publication number
JP2014520787A5
JP2014520787A5 JP2014517822A JP2014517822A JP2014520787A5 JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5 JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014517822 A JP2014517822 A JP 2014517822A JP 2014520787 A5 JP2014520787 A5 JP 2014520787A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517822A
Other languages
English (en)
Japanese (ja)
Other versions
JP6122427B2 (ja
JP2014520787A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063249 external-priority patent/WO2013004818A1/en
Publication of JP2014520787A publication Critical patent/JP2014520787A/ja
Publication of JP2014520787A5 publication Critical patent/JP2014520787A5/ja
Application granted granted Critical
Publication of JP6122427B2 publication Critical patent/JP6122427B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517822A 2011-07-07 2012-07-06 ダルナビル複合製剤 Active JP6122427B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11173067.7 2011-07-07
EP11173067 2011-07-07
PCT/EP2012/063249 WO2013004818A1 (en) 2011-07-07 2012-07-06 Darunavir combination formulations

Publications (3)

Publication Number Publication Date
JP2014520787A JP2014520787A (ja) 2014-08-25
JP2014520787A5 true JP2014520787A5 (OSRAM) 2015-08-13
JP6122427B2 JP6122427B2 (ja) 2017-04-26

Family

ID=46551505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517822A Active JP6122427B2 (ja) 2011-07-07 2012-07-06 ダルナビル複合製剤

Country Status (24)

Country Link
US (3) US20140142070A1 (OSRAM)
EP (1) EP2729130B1 (OSRAM)
JP (1) JP6122427B2 (OSRAM)
KR (1) KR102058097B1 (OSRAM)
CN (1) CN103826616B (OSRAM)
AU (1) AU2012280198B2 (OSRAM)
BR (1) BR112014000290B1 (OSRAM)
CA (1) CA2838659C (OSRAM)
CY (1) CY1121999T1 (OSRAM)
DK (1) DK2729130T3 (OSRAM)
EA (1) EA026587B1 (OSRAM)
ES (1) ES2651212T3 (OSRAM)
HR (1) HRP20171889T1 (OSRAM)
HU (1) HUE035241T2 (OSRAM)
IL (1) IL229933A (OSRAM)
LT (1) LT2729130T (OSRAM)
MX (1) MX343689B (OSRAM)
NO (1) NO2729130T3 (OSRAM)
PL (1) PL2729130T3 (OSRAM)
PT (1) PT2729130T (OSRAM)
RS (1) RS56667B1 (OSRAM)
SI (1) SI2729130T1 (OSRAM)
SM (1) SMT201700574T1 (OSRAM)
WO (1) WO2013004818A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
AU2013225981A1 (en) * 2012-03-01 2014-10-02 Gilead Sciences, Inc. Spray dried formulations
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana
BR112019002120A2 (pt) * 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
WO2018029566A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited A high drug loaded tablet composition for treating hiv
WO2018064071A1 (en) * 2016-09-27 2018-04-05 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
JP2020528409A (ja) * 2017-07-20 2020-09-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Hivの処置における使用のための、ダルナビル、コビシスタット、エムトリシタビン、及びテノホビルアラフェナミドを含む組成物
WO2020064980A1 (en) 2018-09-28 2020-04-02 Janssen Sciences Ireland Unlimited Company Methods of treating and preventing neuropsychiatric and/or neurocognitive complications in patients infected with hiv
WO2021180963A1 (en) 2020-03-13 2021-09-16 Janssen Sciences Ireland Unlimited Company A protease inhibitor regimen for treating subjects infected with hiv
CN119700779B (zh) * 2024-11-28 2025-11-04 安徽贝克生物制药有限公司 一种达芦那韦和考比司他复合片剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
ATE500823T1 (de) 1998-06-23 2011-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Arzneimittel zur behandlung von hiv-infizierten säugetieren
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
PT2767539T (pt) 2002-05-16 2017-08-28 Janssen Sciences Ireland Uc Formas pseudopolimórficas de um inibidor de protease de hiv
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
AU2007256931B2 (en) 2006-05-30 2013-01-24 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008052033A2 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
ES2602784T3 (es) 2007-02-23 2017-02-22 Gilead Sciences, Inc. Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos
EP2170293A2 (en) * 2007-06-25 2010-04-07 Tibotec Pharmaceuticals Combination formulations comprising darunavir and etravirine
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
MX2010005488A (es) 2007-11-20 2010-06-01 Janssen Pharmaceutica Nv Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina.
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
HRP20151357T1 (hr) 2008-05-02 2016-01-29 Gilead Sciences, Inc. Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
EA021313B1 (ru) * 2009-02-06 2015-05-29 Джилид Сайэнс, Инк. Таблетки для комбинированной терапии
SI2477992T1 (sl) * 2009-09-17 2017-05-31 Mylan Laboratories Limited Postopki za pripravo darunavirja in njega amorfne oblike
EP2568810B1 (en) 2010-05-10 2018-09-19 Hetero Research Foundation Darunavir compositions
US20140142174A1 (en) 2011-07-07 2014-05-22 Urbain Alfons C. Delaet Darunavir formulations
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
EP3240793A1 (en) 2015-01-03 2017-11-08 Mylan Laboratories Ltd. Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof

Similar Documents

Publication Publication Date Title
JP2011093937A5 (OSRAM)
JP2013539946A5 (OSRAM)
JP2013531034A5 (OSRAM)
JP2013531018A5 (OSRAM)
JP2014503786A5 (OSRAM)
JP2012023335A5 (OSRAM)
JP2014026276A5 (OSRAM)
JP2014026274A5 (OSRAM)
JP2014026275A5 (OSRAM)
JP2014505137A5 (OSRAM)
JP2015500269A5 (OSRAM)
JP2012204203A5 (OSRAM)
JP2013064178A5 (OSRAM)
JP2014189812A5 (OSRAM)
JP2014520787A5 (OSRAM)
JP2015107586A5 (OSRAM)
JP2012193264A5 (OSRAM)
JP2012190699A5 (OSRAM)
JP2014531903A5 (OSRAM)
JP2011233516A5 (OSRAM)
JP2014534151A5 (OSRAM)
JP2014520786A5 (OSRAM)
JP2014005521A5 (OSRAM)
JP2013016377A5 (OSRAM)
JP2015127764A5 (OSRAM)